Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IVF.O
IVF.O logo

IVF.O Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.710
Open
2.640
VWAP
2.61
Vol
24.11K
Mkt Cap
3.63M
Low
2.522
Amount
63.04K
EV/EBITDA(TTM)
--
Total Shares
1.39M
EV
14.72M
EV/OCF(TTM)
--
P/S(TTM)
0.05
INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
Show More

Events Timeline

(ET)
2026-03-05
09:10:00
INVO Fertility Adopts Time-Lapse Incubation Technology at Wisconsin Clinic
select
2026-03-03 (ET)
2026-03-03
09:00:00
INVO Fertility Joins Progyny Network
select
2026-02-19 (ET)
2026-02-19
08:40:00
INVO Fertility Completes Acquisition of Family Beginnings
select
2026-02-11 (ET)
2026-02-11
08:40:00
INVO Fertility Secures Patent for INVOcell Device
select
2026-02-04 (ET)
2026-02-04
09:10:00
INVO Fertility CEO Highlights Company's Growth Outlook
select
2026-02-02 (ET)
2026-02-02
17:00:00
INVO Fertility Files to Sell 9.47M Shares of Common Stock
select
2025-12-30 (ET)
2025-12-30
16:10:00
INVO Fertility Appoints New CFO
select
2025-12-17 (ET)
2025-12-17
16:50:00
INVO Fertility Files to Sell 7.37M Shares of Common Stock
select

News

Newsfilter
8.5
03-25Newsfilter
INVO Fertility Announces 1-for-5 Reverse Stock Split
  • Reverse Split Implementation: INVO Fertility announced a 1-for-5 reverse stock split effective March 27, 2026, which will reduce the outstanding shares from approximately 8,077,095 to about 1,615,419, thereby increasing the per-share price and enhancing market perception.
  • Trading Symbol Unchanged: Post-split, the company's common stock will continue to trade under the same symbol 'IVF' on the Nasdaq Capital Market, which will help maintain investor recognition and market stability.
  • Shareholder Rights Adjustment: All shareholders will have their holdings adjusted according to the reverse split ratio, with every 5 shares exchanged for 1 share, ensuring no loss of shareholder equity while providing cash compensation for fractional shares.
  • Market Strategy Focus: INVO Fertility is dedicated to expanding assisted reproductive technology (ART) services, planning to enhance market share by establishing and operating more fertility clinics, and the reverse split will provide greater flexibility for future capital operations.
moomoo
2.0
03-25moomoo
INVO FERTILITY TO IMPLEMENT 1:5 REVERSE STOCK SPLIT STARTING MARCH 27, 2026, BEFORE MARKET OPENING
  • Announcement of Stock Split: Invofertility has announced a 1:5 reverse stock split.

  • Effective Date: The reverse stock split will take effect on March 27, 2026, during pre-market trading.

Newsfilter
3.5
03-05Newsfilter
INVO Fertility Integrates Time-Lapse Incubation Technology
  • Technology Adoption: INVO Fertility has integrated time-lapse incubation technology at its Wisconsin clinic, aiming to enhance laboratory care quality and patient service, reflecting the company's commitment to modern reproductive treatments.
  • Significant Patient Benefits: Continuous embryo monitoring through time-lapse imaging provides detailed developmental insights, aiding embryologists in making informed clinical decisions, thereby improving embryo selection success rates and increasing patient engagement.
  • Consistency in Care: Patients can receive video records of their embryo's development without added complexity, which not only enhances their understanding of the process but also boosts their confidence in the treatment.
  • Strategic Investment Focus: The adoption of this technology underscores INVO Fertility's commitment to investing in advanced technologies, aiming to expand access to fertility care through ongoing innovation and strengthen its competitive position in the reproductive services market.
Newsfilter
8.5
02-19Newsfilter
INVO Fertility Completes Acquisition of Family Beginnings Clinic
  • Acquisition Completed: INVO Fertility has successfully closed the acquisition of Family Beginnings for $760,000, marking a significant milestone in the company's strategy to expand its network of fertility care centers, which is expected to enhance patient service quality and accessibility.
  • Financial Performance: Family Beginnings generated approximately $1 million in revenue and $200,000 in net income for the nine months ended September 30, 2025, accounting for about 18% of INVO's clinic revenue during the same period, indicating its solid market position.
  • Leadership Continuity: The existing medical leadership and care teams at Family Beginnings will remain in place post-acquisition, ensuring continuity of patient care while benefiting from INVO's clinical resources and technological investments to enhance service levels.
  • Strategic Expansion: This acquisition aligns closely with INVO's strategic goals to increase market share through organic growth and targeted acquisitions, with CEO Steve Shum emphasizing the importance of this transaction in enhancing the company's geographic footprint and service capabilities.
moomoo
8.5
02-19moomoo
INVO FERTILITY COMPLETES PURCHASE OF INDIANA FERTILITY CLINIC "FAMILY BEGINNINGS"
  • Acquisition Announcement: Invofertility has completed the acquisition of an Indiana-based fertility clinic named "Family Beginnings."

  • Focus on Fertility Services: The acquisition aims to enhance fertility services and support for families seeking assistance in starting or expanding their families.

Newsfilter
8.5
02-11Newsfilter
INVO Fertility Secures New Patent Protection
  • Patent Protection Expansion: INVO Fertility announced the final issuance of U.S. Patent No. 12,544,204 B2 on February 10, 2026, covering its modified INVOcell® device, ensuring intellectual property protection until 2040, thereby enhancing the company's competitive edge in the fertility technology market.
  • Innovative Medical Device: INVOcell is the world's first FDA-cleared intravaginal culture system that allows fertilization and early embryo development to occur within a woman's body, offering a more natural alternative to traditional in vitro fertilization, which is expected to attract more patients seeking fertility treatments.
  • Design Simplification: The newly patented device features a simplified design with a single main chamber, eliminating the microchamber based on clinical feedback, aimed at enhancing user experience and improving treatment outcomes, thus driving further growth in the fertility market.
  • Strategic Market Support: CEO Steve Shum stated that the patent issuance marks an important milestone in strengthening INVO Fertility's intellectual property foundation, supporting the company's mission to deliver high-quality fertility care through ongoing innovation, which is expected to facilitate future business growth.

Valuation Metrics

The current forward P/E ratio for INVO Fertility Inc (IVF.O) is 0.00, compared to its 5-year average forward P/E of -0.61. For a more detailed relative valuation and DCF analysis to assess INVO Fertility Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.61
Current PE
0.00
Overvalued PE
-0.01
Undervalued PE
-1.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.09
Current EV/EBITDA
-2.39
Overvalued EV/EBITDA
0.20
Undervalued EV/EBITDA
-0.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.45
Current PS
1.68
Overvalued PS
0.67
Undervalued PS
0.22

Financials

AI Analysis
Annual
Quarterly

Whales Holding IVF.O

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is INVO Fertility Inc (IVF.O) stock price today?

The current price of IVF.O is 2.61 USD — it has decreased -4.04

What is INVO Fertility Inc (IVF.O)'s business?

INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.

What is the price predicton of IVF.O Stock?

Wall Street analysts forecast IVF.O stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVF.O is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is INVO Fertility Inc (IVF.O)'s revenue for the last quarter?

INVO Fertility Inc revenue for the last quarter amounts to 1.76M USD, increased 22.60

What is INVO Fertility Inc (IVF.O)'s earnings per share (EPS) for the last quarter?

INVO Fertility Inc. EPS for the last quarter amounts to -6.14 USD, decreased -94.92

How many employees does INVO Fertility Inc (IVF.O). have?

INVO Fertility Inc (IVF.O) has 28 emplpoyees as of April 05 2026.

What is INVO Fertility Inc (IVF.O) market cap?

Today IVF.O has the market capitalization of 3.63M USD.